# REGN10597 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/regn10597

> The next catalyst for REGN10597, sponsored by REGENERON PHARMACEUTICALS, INC. (REGN), is its topline data readout, Jun to Sep 2028.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | REGN10597 |
| Codes | REGN10597 |
| Sponsor | REGENERON PHARMACEUTICALS, INC. (REGN) https://sec-api.dev/companies/regn/catalysts |
| Indications | [Non Small Cell Lung Cancer](https://sec-api.dev/indications/non-small-cell-lung-cancer), [Ovarian Cancer](https://sec-api.dev/indications/ovarian-cancer) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Jun to Sep 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06787612 (Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-06-30 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." https://clinicaltrials.gov/study/NCT06787612

### June 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06787612 (Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-06-30 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." https://clinicaltrials.gov/study/NCT06787612

### Dec 2029 to Mar 2030: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Non Small Cell Lung Cancer; NSCLC.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06465329 (A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2029-12-04 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." https://clinicaltrials.gov/study/NCT06465329

### December 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Non Small Cell Lung Cancer; NSCLC.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06465329 (A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2029-12-04 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." https://clinicaltrials.gov/study/NCT06465329

## Same indication

- [Domvanalimab](https://sec-api.dev/pdufa/domvanalimab) (RCUS)
- [INCB123667](https://sec-api.dev/pdufa/incb123667) (INCY)
- [Iph5201 + durvalumab + standard chemotherapy](https://sec-api.dev/pdufa/iph5201-durvalumab-standard-chemotherapy) (IPHA)
- [Luveltamab tazevibulin](https://sec-api.dev/pdufa/luveltamab-tazevibulin) (STRO)
- [Mirvetuximab soravtansine](https://sec-api.dev/pdufa/mirvetuximab-soravtansine) (ABBV)
- [Mirvetuximab soravtansine plus bevacizumab](https://sec-api.dev/pdufa/mirvetuximab-soravtansine-plus-bevacizumab) (ABBV)
- [Nai + pembrolizumab](https://sec-api.dev/pdufa/nai-pembrolizumab) (IBRX)
- [LYNPARZA® (olaparib)](https://sec-api.dev/pdufa/olaparib) (AZN)
- [Pamiparib capsule](https://sec-api.dev/pdufa/pamiparib) (ONC)
- [Lifyorli™ (relacorilant)](https://sec-api.dev/pdufa/relacorilant) (CORT)
- [Rina-s](https://sec-api.dev/pdufa/rina-s) (GMAB)
- [Sacituzumab tirumotecan](https://sec-api.dev/pdufa/sacituzumab-tirumotecan) (MRK)
- [IBTROZI (taletrectinib)](https://sec-api.dev/pdufa/taletrectinib) (NUVB)
- [Telisotuzumab vedotin](https://sec-api.dev/pdufa/telisotuzumab-vedotin) (ABBV)
- [Ubamatamab](https://sec-api.dev/pdufa/ubamatamab) (REGN)
- [Vudalimab](https://sec-api.dev/pdufa/vudalimab) (XNCR)

Calendar months: [June 2028](https://sec-api.dev/fda-calendar/2028-06)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/regn10597.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "REGN10597 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/regn10597

```bibtex
@misc{secapidev_pdufa_regn10597_20261116,
  title        = {REGN10597 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/regn10597}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_regn10597_20261116","title":"REGN10597 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/regn10597","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
